Control of blood glucose is a fundamental goal in the treatment of diabetes mellitus. Glycation of l-lysine can lower blood glucose and advanced glycation end product (AGE) free adducts can be excreted in the urine. Lysine, an inexpensive amino acid, can be administered orally or parentally, and can be incorporated into a stereocomplex matrix as a time released preparation. In patients who suffer from diabetes and concomitant renal insufficiency who cannot clear sufficient quantities of AGE free adducts enantiomeric mixtures of lysine will lower blood glucose and AGEs since d-lysine has been shown to decrease protein glycation and lower hemoglobin Alc. This invention is not intended to replace insulin or oral hypoglycemic agents but is does offer patients a low cost and probably safe complementary therapy for the treatment of diabetes mellitus. In addition to the treatment of diabetes and its complications, this invention could lower AGE burden and slow or ameliorate some of the consequences of aging.
